ANNUAL REPORT

LIFEHOUSE GYNAECOLOGICAL ONCOLOGY GROUP

2016

Prepared by

Professor Jonathan Carter

MBBS, DipRACOG, FACS, FRANZCOG, MS, MD, CGO
Professor Gynaecological Oncology, The University of Sydney
Head, Lifehouse Gynaecological Oncology Group

Providing Excellence in
Teaching, Research, Education, Patient Care, Administration
# Table of Contents

Introduction ........................................................................................................................................... 4  
Highlights ............................................................................................................................................... 5  
Summary Statistics .................................................................................................................................. 6  
- Overall Activity ...................................................................................................................................... 6  
- New Cancers ......................................................................................................................................... 6  
- In Patient ............................................................................................................................................... 6  
- Out Patient ........................................................................................................................................... 6  
- Major Surgery ....................................................................................................................................... 6  
- Minor Surgery ....................................................................................................................................... 7  
- LOS ....................................................................................................................................................... 7  
- KPI’s ....................................................................................................................................................... 7  
- AE’s Grade 3 & 4 ...................................................................................................................................... 7  
- Meeting Attendance ............................................................................................................................ 7  

Publications ............................................................................................................................................... 8  
International Presentations ...................................................................................................................... 10  
Book Chapters ......................................................................................................................................... 10  
National Presentations ............................................................................................................................. 10  
State Presentations .................................................................................................................................... 12  
Local and Regional Presentations ........................................................................................................... 12  
Abstracts .................................................................................................................................................. 14  
Administrative Responsibilities & Committees ......................................................................................... 14  
PhD & Research Supervision .................................................................................................................... 15  
Grant, Trial & Manuscript Reviews 2016 ..................................................................................................... 16  
RANZCOG Activities ............................................................................................................................... 18  
Ethics Submissions ................................................................................................................................. 18  
Grants Submissions ............................................................................................................................... 19  
Memberships in Professional Organizations ............................................................................................... 19  
Editorial Committee ............................................................................................................................... 19  
Course Organization or Instruction .......................................................................................................... 19  
Invited Lectureship, Guest, Program Chair, Grand Rounds Presentations ............................................... 20  
Teaching, Medical Student & University Activities ................................................................................... 20  
Courses & Conferences Attended ............................................................................................................ 21  
Fundraising, Media ............................................................................................................................... 22  
Research .................................................................................................................................................... 23
Introduction

It is an honor and privilege, as Head of the Lifehouse Gynaecologic Oncology Group, to present the 2016 Annual Report for the Lifehouse Gynaecologic Oncology Group.

This year concludes our 3rd year within Lifehouse. My Department continues to develop and expand. Our senior medical staff comprise myself, A/Prof Selvan Pather, A/Prof Sam Saidi and A/Prof Trevor Tejada-Berges. Our senior nurses are Shannon Philp, our Nurse Practitioner and Belinda Zielony our Clinical Nurse Consultant. Dr. Luciano Rangel from Brazil and Dr. Pearl Tong from Singapore are our Fellows and Dr. King Man Wan our Lifehouse Gynaecologic Oncology Registrar. Stephen Cotterell remains our data manager and programmer for our Database and Patient Management System. Our ever faithful and reliable Christine Young is our Patient Navigator.
Highlights

1. Prof Carter was invited to write an Editorial for Medical Journal of Australia on the Renewal of the National Cervical Cancer Screening Program, which subsequently led to media interviews on Channel 9 and ABC Radio National (http://www.abc.net.au/radionational/programs/healthreport/cervical-cancer-screening/7938108#transcript)

2. A/Prof Marcelo Nascimento was appointed to the Unit and to the newly formed Advanced GI Surgical Program at RPAH.

3. A/Prof Pather was a member of the Renewal Panel for the National Cervical Screening Programme.

4. A/Prof Saidi passed his written examination of the CGO examination on 19th July 2016 and was subsequently awarded full CGO certification on 29th November 2016.

5. A/Prof Saidi commenced Rapid Access Hysteroscopy service.

6. A/Prof Tejada-Berges was appointed to the Educational Committee of the International Gynecologic Cancer Society (IGCS).

7. A/Prof Tejada-Berges performed the 100th robotic surgery at Chris O’Brien Lifehouse on 2nd November 2016.

8. A/Prof Tejada-Berges passed the oral component of CGO Examination on 20th November 2016.

9. Belinda Zielony was appointed to Cancer Nurses Society of Australia (CNSA) Gynaecological Specialist Practice Network Committee.
### Summary Statistics

#### Overall Activity

<table>
<thead>
<tr>
<th>Year</th>
<th>Inpatients</th>
<th>Outpatients</th>
<th>New Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>669</td>
<td>6162</td>
<td>229</td>
</tr>
<tr>
<td>2015</td>
<td>749</td>
<td>6181</td>
<td>224</td>
</tr>
<tr>
<td>2016</td>
<td>825</td>
<td>7214</td>
<td>252</td>
</tr>
</tbody>
</table>

#### New Cancers

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>50</td>
<td>70</td>
<td>45</td>
<td>61</td>
<td>3</td>
<td>229</td>
</tr>
<tr>
<td>2015</td>
<td>48</td>
<td>64</td>
<td>61</td>
<td>48</td>
<td>3</td>
<td>224</td>
</tr>
<tr>
<td>2016</td>
<td>60</td>
<td>68</td>
<td>56</td>
<td>60</td>
<td>8</td>
<td>252</td>
</tr>
</tbody>
</table>

#### New Cancers (Break down by tumour site)

<table>
<thead>
<tr>
<th>Year</th>
<th>New Cancers</th>
<th>Cervix</th>
<th>Corpus</th>
<th>Uterine Sarcoma</th>
<th>Ovary</th>
<th>Sex Cord Stromal</th>
<th>Germ Cell</th>
<th>Vulva</th>
<th>Vagina</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>229</td>
<td>40</td>
<td>66</td>
<td>11 (4.8%)</td>
<td>53</td>
<td>3 (1.3%)</td>
<td>2 (0.87%)</td>
<td>14</td>
<td>6.1%</td>
</tr>
<tr>
<td>2015</td>
<td>224</td>
<td>30</td>
<td>63</td>
<td>9 (4%)</td>
<td>62</td>
<td>2 (0.89%)</td>
<td>4 (1.8%)</td>
<td>10</td>
<td>4.5%</td>
</tr>
<tr>
<td>2016</td>
<td>252</td>
<td>31</td>
<td>93</td>
<td>7 (2.8%)</td>
<td>63</td>
<td>4 (1.6%)</td>
<td>3 (1.2%)</td>
<td>15</td>
<td>6%</td>
</tr>
</tbody>
</table>

#### In Patient

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>205</td>
<td>202</td>
<td>109</td>
<td>153</td>
<td>0</td>
<td>669</td>
</tr>
<tr>
<td>2015</td>
<td>177</td>
<td>226</td>
<td>149</td>
<td>197</td>
<td>0</td>
<td>749</td>
</tr>
<tr>
<td>2016</td>
<td>181</td>
<td>233</td>
<td>192</td>
<td>206</td>
<td>13</td>
<td>825</td>
</tr>
</tbody>
</table>

Includes Consults

#### Out Patient

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>1493</td>
<td>1867</td>
<td>1203</td>
<td>1211</td>
<td>388</td>
<td>6162</td>
</tr>
<tr>
<td>2015</td>
<td>1414</td>
<td>1593</td>
<td>1444</td>
<td>1465</td>
<td>265</td>
<td>6181</td>
</tr>
<tr>
<td>2016</td>
<td>1362</td>
<td>1751</td>
<td>1846</td>
<td>1613</td>
<td>642</td>
<td>7214</td>
</tr>
</tbody>
</table>

#### Major Surgery

<table>
<thead>
<tr>
<th>Year</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>60</td>
<td>114</td>
<td>63</td>
<td>114</td>
<td>0</td>
<td>351</td>
</tr>
<tr>
<td>2015</td>
<td>47</td>
<td>95</td>
<td>81</td>
<td>102</td>
<td>1</td>
<td>326</td>
</tr>
<tr>
<td>2016</td>
<td>58</td>
<td>100</td>
<td>81</td>
<td>89</td>
<td>9</td>
<td>337</td>
</tr>
<tr>
<td>Minor Surgery</td>
<td>Carter</td>
<td>Pather</td>
<td>Saidi</td>
<td>Tejada-Berges</td>
<td>Other</td>
<td>Total</td>
</tr>
<tr>
<td>---------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td>----------------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>2014</td>
<td>118</td>
<td>67</td>
<td>29</td>
<td>27</td>
<td>0</td>
<td>241</td>
</tr>
<tr>
<td>2015</td>
<td>110</td>
<td>95</td>
<td>54</td>
<td>65</td>
<td>0</td>
<td>324</td>
</tr>
<tr>
<td>2016</td>
<td>106</td>
<td>125</td>
<td>94</td>
<td>92</td>
<td>7</td>
<td>424</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LOS</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2.84</td>
<td>2.74</td>
<td>2.12</td>
<td>3.66</td>
<td>-</td>
<td>2.84</td>
</tr>
<tr>
<td>2015</td>
<td>2.85</td>
<td>2.78</td>
<td>2.55</td>
<td>2.89</td>
<td></td>
<td>2.77</td>
</tr>
<tr>
<td>2016</td>
<td>3.22</td>
<td>2.97</td>
<td>2.2</td>
<td>2.84</td>
<td></td>
<td>2.81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>KPI's</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>21</td>
<td>21</td>
<td>18</td>
<td>26</td>
<td>0</td>
<td>86</td>
</tr>
<tr>
<td>2015</td>
<td>13</td>
<td>15</td>
<td>15</td>
<td>19</td>
<td>0</td>
<td>62</td>
</tr>
<tr>
<td>2016</td>
<td>18</td>
<td>26</td>
<td>19</td>
<td>19</td>
<td>5</td>
<td>87</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AE's Grade 3 &amp; 4</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>4</td>
<td>5</td>
<td>1</td>
<td>10</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>2015</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>13</td>
</tr>
<tr>
<td>2016</td>
<td>8</td>
<td>15</td>
<td>5</td>
<td>6</td>
<td>0</td>
<td>34</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Meeting Attendance</th>
<th>Carter</th>
<th>Pather</th>
<th>Saidi</th>
<th>Tejada-Berges</th>
<th>Other</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014 MDT</td>
<td>37</td>
<td>34</td>
<td>41</td>
<td>41</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2014 M&amp;M</td>
<td>8</td>
<td>6</td>
<td>10</td>
<td>11</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2015 MDT</td>
<td>41</td>
<td>36</td>
<td>40</td>
<td>37</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2015 M&amp;M</td>
<td>8</td>
<td>7</td>
<td>9</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2016 MDT</td>
<td>35</td>
<td>35</td>
<td>40</td>
<td>39</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2016 M&amp;M</td>
<td>9</td>
<td>7</td>
<td>10</td>
<td>11</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Publications

Carter


**Pather**


**Saidi**


**Tejada-Berges**


**Philp**


**Other**

International Presentations

Philp

Book Chapters

Pather
3. Anderson L, Pather S, Wright G, Hammond I, Saville M. National Cervical Screening Programme Clinical question: Follow-up of high grade squamous lesions post-treatment: cytology and HPV testing at 12 vs at 12 and 24 mo (body of evidence· screen literature updates )— NHMRC in press

National Presentations

Carter
**Pather**


**Tejada-Berges**

1. **Tejada-Berges T**. Cervical Disease Management: Excisional Techniques. ASCCP Course and Update. Gold Coast, QLD. 2nd April 2016
2. **Tejada-Berges T**. Colposcopy in the Young and Old. ASCCP Course and Update. Gold Coast, QLD. 3rd April 2016.
4. **Tejada-Berges T**. Colposcopy in the Young and Old. ASCCP Course and Update. Darwin, NT. 18th September 2016.
5. **Tejada-Berges T**. Vulvar intra-epithelial neoplasia (VIN) and anal intra-epithelial neoplasia (AIN). ASCCP Course and Update. Darwin, NT. 18th September 2016.

**Philp**


**Other**

State Presentations

Pather


Other


Local and Regional Presentations

Carter


Pather


Saidi

2. Saidi S. ASCCP training course. Technique of LEEP and safety aspects. 17th November 2016

Tejada-Berges


**Other**


**Abstracts**

**Carter**

1. **Carter J.** Advances in Gynaecological Cancer Screening. HPV and Vaccination. Chris O’Brien Lifehouse. 1st September 2016

**Pather**

2. Rangel L, Tejada Berges T, **Pather S,** Carter J, Saidi S. Outcomes following treatment of CIN 2/3 in an Australian population. Lifehouse research symposium Lifehouse, Sydney, Australia. 14th October 2016,

**Other**


**Administrative Responsibilities & Committees**

**Carter**

1. **Carter J.** Committee Member Lifehouse Clinical Leadership Committee.
2. **Carter J.** Chairman Lifehouse MDAC Committee.
3. **Carter J.** Chairman Lifehouse Theatre Advisory Committee.
4. **Carter J.** Committee Member Scientific Advisory Panel. The Australian Gynaecological Cancer Foundation.
5. **Carter J.** Committee Member Scientific Advisory Panel. Compass Trial.
6. **Carter J.** Committee Member SLHD Advanced GI Surgical Program Steering Committee.
7. **Carter J.** Committee Member Uro-Oncology Interviews. 5th January 2016  
8. **Carter J.** Committee Member Head Department Breast Service 1st & 3rd March 2016

**Pather**

1. **Pather S.** Member of the guidelines committee for the National Cervical Screening Programme.  
2. **Pather S.** Member of the Morbidity and Mortality Committee Lifehouse.  
3. **Pather S.** CGO Examination Committee, RANZCOG  
4. **Pather S.** Steering Committee Optimising cervical cancer prevention amongst Aboriginal women in rural and remote New South Wales  
5. **Pather S.** Gynaecological Oncology Model Scope of Clinical Practice Committee, 2016  
6. **Pather S.** Executive Member of ASCCP

**Tejada-Berges**

1. **Tejada-Berges T.** Co-opted Member of Australian Society of Colposcopy and Cervical Pathology (ASCCP) Committee of Management. Feb 2016.  
3. **Tejada-Berges T.** Lifehouse Robotic Steering Committee.  
4. **Tejada-Berges T.** Lifehouse Representative to SLHD Surgical Robotics Program Steering Committee

**Philp**

1. **Philp S.** NSW ACI Gynaecological Oncology Nurses Group (GONG) Executive Committee  
2. **Philp S.** CNSA, Gynaecological Oncology Specialist Practice Network (GYN SPN)  
3. **Philp S.** CNSA NP Specialist Practice Network (NP SPN)  
4. **Philp S.** CNSA, GYN SPN, 2016 Pre-Congress workshop committee  
5. **Philp S.** Advisory Team, Preceptorship of visiting Hong Kong Cancer Nurses, Lifehouse, October-November 2016

**Zielony**

1. **Zielony B.** NSW ACI Gynaecological Oncology Nurses & Allied Health Group (GONG) Executive Committee  
2. **Zielony B.** Cancer Nurses Society of Australia (CNSA) Gynaecological Specialist Practice Network Committee Member

**PhD & Research Supervision**

**Carter**

1. **Carter J.** The role of natural treatment in the regression of early cervical dysplasia caused by high risk HPV. A systematic review of the evidence for the effectiveness of natural therapies (Carotenoids/micronutrients) in the regression of cervical dysplasia and high risk HPV. PhD Supervision Dr. Paulette Maroun. University of Technology Sydney. 2016

**Pather**

1. **Pather S.** Dr U Herbst. CIN 2 in an HPV negative population
2. **Pather S.** Pearl Tong. Pyometria, A case report
3. **Pather S.** Pearl Tong. Management of Stage 2 endometrial cancer

**Saidi**
1. **Saidi S.** Eskaroos M. Acceptability of outpatient vs inpatient LEEP biopsy.
2. **Saidi S.** Feddersen J. Bleeding patterns following LEEP biopsy, risk factors and outcomes.
3. **Saidi S.** Grey M. eQOL measurement tool in gynaecological cancer follow-up
5. **Saidi S.** Luciano Rangel. Outcomes following treatment of CIN2/3

**Philp**
1. **Philp S.** Associate Supervisor for Doctor of Philosophy Candidate: Testing the feasibility of a brief nurse-led lifestyle intervention for women with type 1 endometrial cancer, School of Nursing, The University of Sydney. Thesis submitted

**Grant, Trial & Manuscript Reviews 2016**

**Carter**
2. **Carter J.** Manuscript review. Manuscript Number IGC-D-16-00020. Improved detection rate of ovarian cancer using a two-step triage model of the Risk of Malignancy Index (RMI) and expert sonography in an outpatient screening setting. 6th February 2016
3. **Carter J.** Manuscript review. Manuscript Number IJG-D-16-00121. The prognosis of high risk early stage cervical cancer patients who did not receive postoperative concurrent chemoradiotherapy. 9th February 2016
4. **Carter J.** Manuscript review. Manuscript Number mj15.01404. Quality of salpingoophorectomy for ovarian cancer prevention: still room for improvement. 16th February 2016
8. **Carter J.** Manuscript Review. IJG-D-16-00348. Predictive value of the serum HE4 and CA125 concentrations for the lymphatic metastasis of endometrial cancer. 6th April 2016


**Pather**


2. **Pather S.** ID CJOG-2016-0347 Relationship between obesity and symptomatology in women undergoing hysterectomy for prolapse. Journal of Obstetrics and Gynaecology. 2nd October 2016


4. **Pather S.** ANZJOG-2016-0326 entitled "Initial observation of CIN2 does not appear to reduce quality of life in women under 25 years of age. December 2016.

**Saidi**


**Tejada-Berges**


2. **Tejada-Berges T.** Supportive Care in Cancer, Manuscript review: Manuscript No: JSCC-D-16-00642. September 2016.


**Philp**

1. **Philp S.** Abstract review: International Conference on Cancer Nursing (ICCN), Hong Kong, China, September 2016

2. **Philp S.** Australian Journal of Cancer Nursing, Manuscript review, ID 2016-3

3. **Philp S.** European Journal of Cancer Care, Manuscript review, ECC-2015-0190.R2

4. **Philp S.** European Journal of Cancer Care, Manuscript review, ECC-2015-0190.R1

5. **Philp S.** Cancer Council NSW, Understanding Ovarian Cancer booklet, June 2016
Other
1. **Wan KM.** Peer reviewer for Trials Journal, Protocol TRLS-D-16-00265R1 21st July 2016
2. **Wan KM.** Peer reviewer for Trials Journal, Protocol TRLS-D-16-00265R2 3rd October 2016

RANZCOG Activities

Pather
1. **Pather S.** College Examiner for the CGO Subspeciality examinations: College House November 2016

Saidi
1. **Saidi S.** RANZCOG basic surgical skills workshop. Trainer. 20th-21st Feb 2016

Tejada-Berges
1. **Tejada-Berges T.** MRANZCOG Revision Course: Surgical Pelvic Anatomy, Rydges Hotel, North Sydney, 24th October 2016.

Other
1. **Wan KM.** Accepted for Gynaecological Oncology (CGO) Training program for 2017, Subspecialties Training Program, RANZCOG
2. **Wan KM.** RANZCOG Basic Surgical Skills Course Facilitator, Kolling Institute - Royal North Shore Hospital, 21st February 2016

Ethics Submissions

Pather
1. **Pather S.** Pelvic sepsis following a hysteroscopy for pyometria. A case report.
2. Herbst U, Wong E, **Pather S.** Protocol No X15-0389 & HREC/15/RPAH/532 - “Immunohistochemistry for HPV testing on archived tissue in women with biopsy proven high grade cervical dysplasia and negative HPV testing”
3. Tong P, **Pather S.** Protocol No X16-0476 & LNR/16/RPAH/680 - “The demographics and outcomes of women with Stage II endometrial carcinoma managed in Australia (2005-2007)
Grants Submissions

Carter
1. Obermair A, Quinn M, Brennan D, Armes J, Janda M (CI), Carter J (AI). Improving the treatment for women with early stage cancer of the uterus (fMMe). 2016 NHMRC Project Grant

Memberships in Professional Organizations

Carter
7. Carter J. University of Sydney Association of Professors.

Editorial Committee

Pather
1. Pather S. Austin Journal of Obstetrics and Gynaecology

Course Organization or Instruction

Pather
1. Pather S. ASCCP treatment course in Gynaecologic Dysplasia. Lifehouse 19 November 2016

Philp
1. Philp S. Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney

Zielony

Other
1. Tong P. Facilitator at ASCCP LEEP Workshop. Sydney 19th November 2016
Invited Lectureship, Guest, Program Chair, Grand Rounds Presentations

**Philp**
1. Philp S. Chair of session. ACI GONG, “Cervical Cancer”, RPAH, 3 June 2016

**Tejada-Berges**

**Other**
2. Wan K, “Approach to PV Bleeding for Interns” Royal Prince Alfred Hospital. 9th November 2016

Teaching, Medical Student & University Activities

**Carter**

**Pather**
1. Pather S. Co-organizer: Cervical Cancer Pathology, University of Sydney, 21nd October, 2016.
3. Pather S. Student Lectures Med 4 Post menopausal bleeding and Cervical dysplasia/cancer 15/03/16; 17/05/16; 19/07/16; 04/10/16

**Saidi**
1. Saidi S. University of Sydney Medical School. SCORPIO teaching session. Smears and cytology. 21st Oct 2016
2. Saidi S. University of Sydney Medical School. Part 2 OSCE examiner. 1st Nov 2016
3. Saidi S. University of Sydney Medical School. Stage 2 PPD interviews. 6th - 14th Nov 2016.

**Philp**
1. Philp S. Lecturer and Course Coordinator, Cancer and Haematology Nursing, Sydney Nursing School, The University of Sydney

**Tejada Berges**


**Other**

1. **Rangel L, Wan K, Tong P, Pather S.** Colposcopy and treatment of dysplasia. Medical students Scorpio teaching activity. Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia, 21 October 2016.

**Courses & Conferences Attended**

**Philp**

1. **Philp S.** 19th Annual CNSA Winter Congress, Cairns, May 2016


3. **Philp S.** Nursing Strategy Day Workshop, Lifehouse, July 2016

**Tejada Berges**

1. **Tejada-Berges T.** BRCA: Challenges and Opportunities, Sixth International Symposium on Hereditary Breast and Ovarian Cancer. Centre Mont-Royal, Montréal, Canada. 10-13 May, 2016.

**Other**

1. **Tong P.** Attendance ASGO ASM Conference. Cradle Mountain Tasmania, 19-21st May 2016

2. **Wan KM.** Attendance ASGO ASM Conference. Cradle Mountain Tasmania, 19-21st May 2016
Fundraising, Media

Carter


Saidi
1. **Saidi S.** Chairman's lunch presentation. Supra-radical surgery in Ovarian Cancer – the case for a specialised centre. Chris O'Brien Lifehouse. 18th March 2016

Tejada-Berges
1. **Tejada-Berges T.** "Breakfast of Champions". Australia School Fundraiser for Chris O'Brien Lifehouse. 6th May 2016.
## Research

<table>
<thead>
<tr>
<th>LH Reference</th>
<th>Study Title</th>
<th>Protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH13.003</td>
<td>PARAGON (ANZGOG0903) Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms</td>
<td>ANZGOG0903</td>
</tr>
<tr>
<td>LH13.036</td>
<td>A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (OVAR 16)</td>
<td>AGO-OVER 16/VEG11065</td>
</tr>
<tr>
<td>LH13.039</td>
<td>Clinical Study No. 1199.15 Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer (OVAR 12)</td>
<td>AGO-OVER 16/VEG11065</td>
</tr>
<tr>
<td>LH13.055</td>
<td>IBCSG 24-02/BIG 2-02 : A Phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer (SOFT)</td>
<td>IBCSG 24-02/BIG 2-02</td>
</tr>
<tr>
<td>LH13.056</td>
<td>ANZGOG 0902 : A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (The OUTBACK Trial)</td>
<td>ANZGOG 0902</td>
</tr>
<tr>
<td>LH14.018</td>
<td>An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer - ICON8</td>
<td>Icon8</td>
</tr>
<tr>
<td>LH14.024</td>
<td>AGO-OVAR 2.21 / ENGOT-ov18 : A Prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer (An ENGOT/GCIG Trial) (OVAR 2.21)</td>
<td>AGO-OVAR 2.21</td>
</tr>
<tr>
<td>LH14.029</td>
<td>EMR 200066_012 : Phase II Randomised Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer</td>
<td>EMR 200066_012</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>LH15.035</td>
<td>Impact of risk-reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high risk women: A multicentre prospective study (WHAM)</td>
<td>WHAM</td>
</tr>
<tr>
<td>LH15.037</td>
<td>Clinical audit of single surgeon experience with Fast Track Surgery in gynaecological patients</td>
<td>Authorised</td>
</tr>
<tr>
<td>LH15.048</td>
<td>The conservative management of young women, up to age 25, with cervical intraepithelial neoplasia (CIN) 2 (PRINCESS)</td>
<td>PRINCESS</td>
</tr>
<tr>
<td>LH15.049</td>
<td>ANZGOG 1301 : A Phase II Randomised Clinical Trial of Mirena ± Metformin ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium (FEMME)</td>
<td>ANZGOG-1301</td>
</tr>
<tr>
<td>LH16.018</td>
<td>Genomic mechanisms underlying long-term response to treatment in serous ovarian cancer: an Australian Ovarian Cancer Study Project (AOCs)</td>
<td>Authorised</td>
</tr>
<tr>
<td>LH16.022</td>
<td>Clinical Study No. M13-694 , A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Participants with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</td>
<td>M13-694</td>
</tr>
<tr>
<td>LH16.023</td>
<td>Immunohistochemistry for HPV testing on archived tissue in women with biopsy proven high grade cervical dysplasia and negative HPV testing</td>
<td></td>
</tr>
<tr>
<td>LH16.025</td>
<td>Understanding End of Life Decision Making in Cancer</td>
<td></td>
</tr>
<tr>
<td>LH16.027</td>
<td>Is Preoperative Carbohydrate Loading Tolerable and Beneficial in Gynaecologic Oncology Surgery</td>
<td>CARB LOADING</td>
</tr>
<tr>
<td>LH16.028</td>
<td>The Role of Alpha-Parvin in Human Endometrial Cancer Cells</td>
<td></td>
</tr>
<tr>
<td>LH16.045</td>
<td>INOVATe - Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care</td>
<td></td>
</tr>
<tr>
<td>LH16.047</td>
<td>An audit of the deliverability of Carboplatin and Weekly Paclitaxel as Adjuvant Therapy for Ovarian Fallopian tube and Primary Peritoneal Cancer Patients</td>
<td></td>
</tr>
</tbody>
</table>